

**MIXED-BACKBONE OLIGONUCLEOTIDES CONTAINING POPS BLOCKS TO  
OBTAIN REDUCED PHOSPHOROTHIOATE CONTENT**  
(Atty Docket No. 47508-423)

5                    This is a continuation-in-part of U.S. provisional application serial number  
60/080321, filed 1 April 1998.

**BACKGROUND OF THE INVENTION**

10            Field of the invention

                 The invention relates to antisense oligonucleotides. In particular, the invention  
relates to modified antisense oligonucleotides having reduced sulfur content.

15            Summary of the related art

20            Mixed-backbone oligonucleotides (MBOs) provide a handle on modulating the  
pharmacological, pharmacodynamic, and pharmacokinetic profiles of antisense  
oligonucleotides. MBOs are currently the best choice as second-generation  
oligonucleotides over PS-oligos. MBOs contain appropriately placed segments of  
phosphorothioate oligodeoxynucleotide (PS-oligo) and one or more other type of  
modified oligodeoxynucleotide or oligoribonucleotide. The advantage of MBOs is that,  
while they retain the advantages of PS-oligo's stability against nuclease and RNase H  
25            activation, the side effects inherent in PS-oligos (immune stimulation, complement  
activation and prolongation of partial thromboplastin time, etc.) can be minimized,  
depending on the nature of modified segment incorporated in MBOs. The positioning  
of the segments of modified oligodeoxynucleotides or oligoribonucleotides in a MBO  
may strongly affect its desired properties. In end-modified MBOs, a segment of PS-  
30            oligo is placed in the center to provide the RNase H activation, and segments of other  
type of modified oligonucleotide are placed at one or both of the 3'- and 5'- ends to  
modulate other antisense properties. End-modified MBOs have proved to be more

effective than the PS-oligos as antisense agents and are currently being evaluated in clinical trials as therapeutic agents.

In certain end-modified MBOs, the existence and nature of modifications at the 2'-position of some nucleosides is important in providing increased duplex affinity and stability towards nucleases. The 2'-0-methylribonucleoside phosphorothioate and the 2'-0-methoxyethoxyribonucleoside phosphodiester are two types of modified nucleotide segments that have been studied most extensively. Incorporation of 2'-0-methylribonucleoside in the MBOs can increase the duplex stability with the target RNA. However, for an increase in nuclease stability, phosphorothioate internucleotide linkages are usually required as 2'-0-methylribonucleoside phosphodiester segments showed reduced nuclease stability. Incorporation of 2'-0-methoxyethoxyribonucleoside also provides an increase in duplex stability, and also demonstrated, *in vitro*, increased nuclease stability even with phosphodiester internucleotide linkages. Both of these types of end-modified MBOs have reduced the PS-oligo-related side effects. Differences in their pharmacokinetic and elimination profiles have been observed, however. The MBOs containing 2'-0-methylribonucleoside phosphorothioate show tissue distribution profiles similar to those of PS-oligos following intravenous administration with a significant improvement in stability and retention in tissues; the MBOs containing 2'-0-methoxyethoxyribonucleoside phosphodiester showed rapid elimination in urine and disposition in kidneys compared to PS-oligo.

There is a need for additional types of MBOs, which can significantly reduce the PS content without compromising the antisense properties, such as duplex stability, nuclease stability, RNase H activity, antisense-based biological activity and tissue disposition. Ideally, such MBOs could be obtained by subtle modifications of the best MBOs available to date.

## BRIEF SUMMARY OF THE INVENTION

5 The invention relates to antisense oligonucleotides. In particular, the invention relates to modified antisense oligonucleotides having reduced sulfur content. The invention provides new MBOs, which have significantly reduced PS content without compromising their antisense properties, such as duplex stability, nuclease stability, Rnase H activity, antisense-based biological activity and tissue disposition. These new MBOs are obtained by subtle modifications of the best MBOs available to date.

10 In a first aspect, the invention provides oligonucleotides containing POPS blocks. POPS blocks are oligonucleotide regions containing alternating nucleoside phosphodiester (PO) and nucleoside phosphorothioates (PS). In certain preferred embodiments, such nucleoside phosphodiester and nucleoside phosphorothioates alternate in a one-to-one manner, *i.e.*, PO-PS-PO-PS-PO-PS. In other preferred  
15 embodiments, such nucleoside phosphodiester and nucleoside phosphorothioates alternate in a two-to-one PO to PS manner (PO-PO-PS-PO-PO-PS) or in a two-to-one PS to PO manner (PS-PS-PO-PS-PS-PO). In still other preferred embodiments, such nucleoside phosphodiester and nucleoside phosphorothioates alternate in a two-to-  
20 two manner (PS-PS-PO-PO) or in a three-to-three manner (PS-PS-PS-PO-PO-PO). In yet additional preferred embodiments, the alternation of such nucleoside phosphodiester and nucleoside phosphorothioates is irregular, provided however, that in such embodiments, a ratio of nucleoside phosphodiester and nucleoside phosphorothioates of from 1:3 to 3:1 is maintained in at least one POPS block.

25 In a second aspect, the invention provides hybrid oligonucleotides comprising one or more POPS block. Hybrid oligonucleotides are described in U.S. Patent No. 5,652,355, which is hereby incorporated by reference. Generally, such hybrid oligonucleotides comprise at least one region of deoxyribonucleoside phosphodiester or phosphorothioates, which is flanked by regions of 2'-O-substituted nucleosides, which may be connected to each other and to the region of deoxyribonucleoside  
30 phosphodiester or phosphorothioates by any type of internucleoside linkage. Thus, in this aspect of the invention, the invention comprises the improvement in a hybrid oligonucleotide of having one or more POPS block as a region of deoxyribonucleoside phosphodiester or phosphorothioates.

In a third aspect, the invention provides inverted hybrid oligonucleotides comprising one or more POPS block. Inverted hybrid oligonucleotides are described in U.S. Patent No. 5,652,356, which is hereby incorporated by reference. Generally, such hybrid oligonucleotides comprise regions of deoxyribonucleoside phosphodiester or phosphorothioates, which flank one or more regions of 2'-O-substituted nucleosides, which may be connected to each other and to the region of deoxyribonucleoside phosphodiester or phosphorothioates by any type of internucleoside linkage. Thus, in this aspect of the invention, the invention comprises the improvement in an inverted hybrid oligonucleotide of having a POPS block as the region of deoxyribonucleoside phosphodiester or phosphorothioates.

5  
10

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows  $^{31}\text{P}$  NMR and MALDI-TOF MS spectra of oligo 6. Underlined letters represent deoxynucleosides; plain letters represent 2'-O-methylribonucleosides; S and O represent phosphorothioate and phosphodiester linkages, respectively.

Figure 2 shows CGE profiles of comparative stability of oligos 1, 2 and 6 towards SVPD (0.004 units/50  $\mu\text{l}$ ) at 37  $^{\circ}\text{C}$  for 24 hr. Intact oligo 1 was approximately 34%. Peak at 16 min. is of internal standard (PS-oligo 25-mer) added after digestion and before CGE analysis.

Figure 3 shows RNase H hydrolysis pattern of the 5'- $^{32}\text{P}$ -labeled RNA phosphodiester 30-mer (5' ACCGCCGCCAGUGAGGCACGCAGCCUU3') in the presence of oligos 1 to 6. Lane - T1, control lane without RNase T1 added; lane +T1, RNase T1 digestion reaction; lane -OH, alkaline hydrolysis reaction; lane-DNA, control RNA lane without any oligo added; lanes oligos 1 to 6, in the presence of oligos 1 to 6 respectively and RNA and RNase H. There was no cleavage in presence of oligos 3, 4 and 5 as they are not substrate for RNase H. Lane oligo X is a treatment in the presence of an oligo which is not included in this disclosure. The structure of the oligos is depicted in Table 1.

Figure 4 shows a comparison of the effects of oligos 1 to 6 on prolongation of aPTT using human blood from healthy volunteer. Each aPTT value is the average of 4 measurements.

Figure 5 shows CGE profiles of extracted samples of oligo 1(B) and oligo 6(D) from mice plasma at 1 hr post-dosing following IV administration. Panel A and C are control oligo 1 and 6. Peak at 15.5 min. is internal control (PS-oligo 25-mer).

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention relates to antisense oligonucleotides. In particular, the invention relates to modified antisense oligonucleotides having reduced sulfur content. The invention provides new MBOs, which have significantly reduced PS content without compromising their antisense properties, such as duplex stability, nuclease stability, RNase H activity, antisense-based biological activity and tissue disposition. These new MBOs are obtained by subtle modifications of the best MBOs available to date.

The patents and publications cited herein indicate the knowledge in the field and are hereby incorporated by reference in entirety. Any conflict between such patent or publication and the present disclosure shall be resolved in favor of the latter.

In a first aspect, the invention provides oligonucleotides containing POPS blocks. POPS blocks are oligonucleotide regions containing alternating nucleoside phosphodiester (PO) and nucleoside phosphorothioates (PS). In certain preferred embodiments, such nucleoside phosphodiester and nucleoside phosphorothioates alternate in a one-to-one manner, *i.e.*, PO-PS-PO-PS-PO-PS. In other preferred embodiments, such nucleoside phosphodiester and nucleoside phosphorothioates alternate in a two-to-one PO to PS manner (PO-PO-PS-PO-PO-PS) or in a two-to-one PS to PO manner (PS-PS-PO-PS-PS-PO). In still other preferred embodiments, such nucleoside phosphodiester and nucleoside phosphorothioates alternate in a two-to-two manner (PS-PS-PO-PO) or in a three-to-three manner (PS-PS-PS-PO-PO-PO). In yet additional preferred embodiments, the alternation of such nucleoside phosphodiester and nucleoside phosphorothioates is irregular, provided however, that in such embodiments, a ratio of nucleoside phosphodiester and nucleoside phosphorothioates of from 1:3 to 3:1 is maintained in at least one POPS block.

POPS blocks according to the invention comprise from about three to about thirty-five nucleosides, and confer upon, or retain within, an oligonucleotide the ability to activate RNase H. Oligonucleotides containing such POPS blocks also retain important antisense properties, such as duplex stability, nuclease stability, RNase H activity, antisense-based biological activity and tissue disposition.

In a second aspect, the invention provides hybrid oligonucleotides comprising one or more POPS block. Hybrid oligonucleotides are described in U.S. Patent No. 5,652,355, which is hereby incorporated by reference. Generally, such hybrid oligonucleotides comprise at least one region of deoxyribonucleoside phosphodiester  
5 or phosphorothioates, which is flanked by regions of 2'-O-substituted nucleosides, which may be connected to each other and to the region of deoxyribonucleoside phosphodiester or phosphorothioates by any type of internucleoside linkage. Thus, in this aspect of the invention, the invention comprises the improvement in a hybrid oligonucleotide of having one or more POPS block as a region of deoxyribonucleoside  
10 phosphodiester or phosphorothioates.

In a third aspect, the invention provides inverted hybrid oligonucleotides comprising one or more POPS block. Inverted hybrid oligonucleotides are described in U.S. Patent No. 5,652,356, which is hereby incorporated by reference. Generally, such  
15 hybrid oligonucleotides comprise regions of deoxyribonucleoside phosphodiester or phosphorothioates, which flank one or more regions of 2'-O-substituted nucleosides, which may be connected to each other and to the region of deoxyribonucleoside phosphodiester or phosphorothioates by any type of internucleoside linkage. Thus, in this aspect of the invention, the invention comprises the improvement in an inverted  
20 hybrid oligonucleotide of having a POPS block as the region of deoxyribonucleoside phosphodiester or phosphorothioates.

In a fourth aspect, the invention provides methods for using oligonucleotides containing one or more POPS blocks to control the expression of specific genes. Such  
25 methods comprise administering oligonucleotides according to the invention to cells or to animals, including humans. These methods may be used to assess gene function, or as a therapeutic approach to the treatment of diseases resulting from aberrant gene expression.

30 Oligonucleotides according to the invention are useful for a variety of purposes. For example, they can be labeled with a reporter group and used as probes in conventional nucleic acid hybridization assays. They can also be used as antisense "probes" of specific gene function by being used to block the expression of a specific



gene in an experimental cell culture or animal system and to evaluate the effect of blocking such specific gene expression. In this use, oligonucleotides according to the invention are preferable to traditional "gene knockout" approaches because they are easier to use and can be used to block specific gene expression at selected stages of development or differentiation. Finally, oligonucleotides according to the invention are useful in the antisense therapeutic approach.

For purposes of the invention, the term "oligonucleotide" includes polymers of two or more deoxyribonucleotide, or any modified nucleoside, including 2'-halo-nucleosides, 2'-O-substituted ribonucleosides, deazanucleosides or any combination thereof. Such monomers may be coupled to each other by any of the numerous known internucleoside linkages. In certain preferred embodiments, these internucleoside linkages may be phosphodiester, phosphotriester, phosphorothioate, or phosphoramidate linkages, or combinations thereof. The term oligonucleotide also encompasses such polymers having chemically modified bases or sugars and/or having additional substituents, including without limitation lipophilic groups, intercalating agents, diamines and adamantane. For purposes of the invention the term "2'-O-substituted" means substitution of the 2' position of the pentose moiety with a halogen (preferably Cl, Br, or F), or an -O-lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl or allyl group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups; or such 2' substitution may be with a hydroxy group (to produce a ribonucleoside), an amino or a halo group, but not with a 2'-H group. Preferably, such oligonucleotides will have from about 12 to about 50 nucleotides, most preferably from about 17 to about 35 nucleotides. Preferably, such oligonucleotides will have a nucleotide sequence that is complementary to a genomic region, a gene, or an RNA transcript thereof. The term complementary means having the ability to hybridize to a genomic region, a gene, or an RNA transcript thereof under physiological conditions. Such hybridization is ordinarily the result of base-specific hydrogen bonding between complementary strands, preferably to form Watson-Crick or Hoogsteen base pairs, although other modes of hydrogen bonding, as well as base stacking can also lead to hybridization. As a practical matter, such hybridization can be



inferred from the observation of specific gene expression inhibition. The gene sequence or RNA transcript sequence to which the modified oligonucleotide sequence is complementary will depend upon the biological effect that is sought to be modified. In some cases, the genomic region, gene, or RNA transcript thereof may be from a virus.

5 Preferred viruses include, without limitation, human immunodeficiency virus (type 1 or 2), influenza virus, herpes simplex virus (type 1 or 2), Epstein-Barr virus, cytomegalovirus, respiratory syncytial virus, influenza virus, hepatitis B virus, hepatitis C virus and papilloma virus. In other cases, the genomic region, gene, or RNA transcript thereof may be from endogenous mammalian (including human)

10 chromosomal DNA. Preferred examples of such genomic regions, genes or RNA transcripts thereof include, without limitation, sequences encoding vascular endothelial growth factor (VEGF), beta amyloid, DNA methyltransferase, protein kinase A, ApoE4 protein, p-glycoprotein, c-MYC protein, BCL-2 protein, protein kinase A and CAPL. In yet other cases, the genomic region, gene, or RNA transcript thereof may be from a

15 eukaryotic or prokaryotic pathogen including, without limitation, Plasmodium falciparum, Plasmodium malarie, Plasmodium ovale, Schistosoma spp., and Mycobacterium tuberculosis.

20 The following examples are intended to further illustrate certain preferred embodiments of the invention and are not intended to be limiting in nature. To carry out the studies, we chose a PS-oligo (18-mer, oligo 1, Table 1) that is complementary to the RI $\alpha$  regulatory subunit of protein kinase A. Oligo 1 has been studied extensively in both *in vitro* and *in vivo* models. In our previous efforts to improve the therapeutic

25 potential of oligo 1, we have studied a MBO (oligo 2), in which four deoxynucleosides from both 3'- and 5'-ends were substituted with 2'-O-methylribonucleosides. Oligo 2 has the anti-tumor activities similar to those of oligo 1, but with a significant improvement in pharmacokinetic and toxic profiles observed in mice and rats. Reduction of PS-oligo-related side effects has also been observed. Oligo 2 is presently

30 being evaluated for its therapeutic potential in human clinical trials.

Table 1. Structures of oligos used in this study and their various parameters

Oligo No.	Sequence & Modifications	T <sub>m</sub> with RNA (°C)	APTT 50% conc. (μg/ml)
1	5' <u>GsCsGsTsGsCsTsCsTsCsAsCsTsGsGsC</u> 3'	62.9	37.1
2	5' GsCsGsUs <u>GsCsCsTsCsCsTsCsAsCsUsGsGsC</u> 3'	72.1	46.6
3	5' GsCsGsUsGsCsCsUsCsCsUsCsAsCsUsGsGsC 3'	84.8	81.9
4	5' GoCoGoUoGoCoCoUoCoCoUoCoAoCoUoGoGoC 3''	87.4	>200
5	5' GsCoGsUoGsCoCsUoCsCoUsCoAsCoUsGoGsC 3'	87.2	>200
6	5' GsCoGsUo <u>GsCsCsTsCsCsTsCsAsCoUsGoGsC</u> 3'	77.3	94.1

O – phosphodiester linkage, s – phosphorothioate linkage, underlined – deoxynucleoside, normal – 2''-0-methylribonucleoside.

5

### Example 1 Design of oligonucleotides

Based on the design of oligo 2, our approach to further minimize the prolongation of aPTT was to reduce the number of phosphorothioate linkages in oligo 2 without compromising the stability towards nucleases. To carry out the studies, first we designed and prepared some model oligonucleotides (Table 1) to provide insights into the relationship between the nature of the oligonucleotides (nucleoside sugar and phosphate backbone) and its impact on nuclease stability and thermodynamic stability with target RNA, and most importantly, the PS-oligo-related side effects. The oligonucleotides were synthesized using β-cyanoethyl phosphoramidite chemistry on a 15 μmol scale (Expedite 8909, Perceptive Biosystems, MA) or on a 0.5 mmol scale (Pharmacia OligoPilot II Synthesizer). The 2'-0-methyl RNA segments with alternative PS/PO internucleotide linkages in oligos 4, 5, and 6 were synthesized by applying the appropriate oxidation reagents in the corresponding synthesis cycles (Beaue Reagent for PS linkage, and iodine for PO linkage). The oligos were purified by preparative reverse-phase HPLC. The oligo products were characterized by CGE, <sup>31</sup>P NMR, and MALDI-TOF MS. These model oligonucleotides included 2'-0-methyloligoribonucleoside phosphorothioate (oligo 3), 2'-0-methyloligoribonucleoside phosphodiester (oligo 4) and 2'-0-methyloligoribonucleoside containing alternative phosphorothioate and phosphodiester linkages (oligo 5).

25

### Example 2 Stability of oligonucleotides

30

In a study to examine the *in vitro* stability of the oligos towards snake venom phosphodiesterase (SVPD), the following experiments were performed. For each reaction, oligo (0.5 A<sub>260</sub> units) was suspended in buffer (50 μl) containing Tris (pH 8.5, 30 mM) and MgCl<sub>2</sub> (15 mM). To each solution, 0.004 units of SVPD from *crotallus durissus* (Boehringer (Mannheim)) was added. The reaction was carried out for 24 hr. at 37 °C. The stability of oligos 1 to 5 is found to be in the order – oligo 3 ≈ oligo 2 ≈ oligo 5 > oligo 1 >> oligo 4. These results suggest that substitution of one phosphorothioate

35

linkage with a phosphodiester in the 2'-O-methylribonucleoside at alternative sites does not adversely affect the stability of oligo 5 towards SVPD, compared with that of oligo 3. In a parallel study, it was found that substitution of the phosphorothioate linkage with a phosphodiester linkage in the PS-oligo (oligo 1, Table 1) reduced the modified oligos' stability towards SVPD (data not shown).

### Example 3

#### Stability and duplex formation of a POPS block-containing oligonucleotide

10

Prompted by the above observation, and the data described later, we designed and prepared a new type of MBO – oligo 6 (Table 1), which contains a PS-oligo segment (nine deoxynucleosides) in the center flanked by five and four 2'-O-methylribonucleosides at both the 3' – and 5'-ends containing alternative phosphorothioate and phosphodiester linkages. The structural nature of oligo 6 was confirmed by <sup>31</sup>P NMR and MALDI-TOF MS analysis (Figure 1).

15

In the study to compare the *in vitro* stability of the oligos toward SVPD, nuclease resistance was assessed as described in Example 2. Oligo 6 was found to have stability similar to that of oligo 2, and have greater stability than oligo 1 (Figure 2). This indicated the structural design of oligo 6 had no adverse effects on the oligo's nuclease stability *in vitro*.

20

In the melting temperature (T<sub>m</sub>) study to compare the oligos' binding affinity to the complementary RNA phosphodiester, T<sub>m</sub> were recorded using a GBC 920 Spectrophotometer (GBC Scientific Equipment, Victoria, Australia). Oligos were mixed with complementary RNA phosphodiester ((30-mer, 5' ACG GCC GCC AGU GAG GAG GCA CGC AGC CUU 3') in a buffer containing 10 mM Pipes, 1 mM EDTA, and 100 mM NaCl. The T<sub>m</sub> values were obtained from the first derivative plots. Oligo 6 showed an increase of 14.4 °C and 5.2 °C in T<sub>m</sub> compared with oligo 1 and oligo 2 respectively (Table 1). Compared with oligo 2, the increase of the binding affinity of oligo 6, as demonstrated by the increase of T<sub>m</sub>, is due to the substitution of four phosphorothioate linkages with phosphodiester linkages and also an additional 2'-O-methylribonucleoside.

25

30

35

### Example 4

#### RNase H activation by a POPS block-containing oligonucleotide

RNase H digestion studies were carried out as follows. For each reaction, the 5' -<sup>32</sup>P-labeled RNA phosphodiester (30-mer, 0.5 pmol), oligo (5 pmol), and glycogen (50 μmol) were mixed in 12 μl of buffer containing 50 mM MgCl<sub>2</sub>, 100 mM KCl, 1 mM DTT, 200 mM Tris (pH 7.5), and 5% glycerol. After annealing, 0.078 unit of RNase H (Pharmacia) was added to each solution. The mixture were then incubated at 37 °C for 10 min. The reactions were then quenched by adding 20 μl of gel loading dye to each reaction mixture. The resultant samples were analyzed by 20% PAGE and subjected to autoradiography. Oligos 2 and 6 showed to have similar cleavage patterns, which differed from that of oligo 1 due to the flanking 2'-O-methylribonucleosides in oligos 2 and 6 (ref. 1) (Figure 3). This study indicated that the MBO design of oligo 6 had no

40

45

adverse impact on the oligo's ability to cleave the complementary RNA in presence of RNase H.

5

#### Example 5

##### PS-mediated side effects of a POPS block-containing oligonucleotide

10 Compared with oligo 2, this newly-designed MBO (oligo 6) has less phosphorothioate content, and thus may have less PS-oligo-related side effects. Next, the effects of oligos 1 to 6 on prolongation of aPTT were compared. The study was to see if oligo 6 with a reduced number of phosphorothioate linkages was indeed able to reduce the PS-oligo-related side effects such as prolongation of aPTT. Plasma was obtained from citrated human blood. Serial dilution of the oligos in 0.9% NaCl UPS (saline) were made to provide final concs. of 6.25, 12.5, 25, 50 and 100 µg/ml of oligo in plasma. After 15 addition of the oligo samples, the plasma was incubated at 37 °C for 15 min., with gentle agitation. Plasma exposed to vehicle in the same ratio (v/v) as the oligos, and untreated plasma served as negative controls. The assay was conducted in duplicate, providing at least 2 replication for each tube. The aPTT test was performed by TOXICON (BEDFORD, MA). The results are depicted in Figure 4. All oligos showed 20 concentration-dependent prolongation of aPTT, but with significant differences among the oligos. The clear differences between oligo 1 (PS-oligo) and oligo 3 (2'-O-methyloligoribonucleoside phosphorothioate) confirmed our previous observation that phosphorothioate linkage of the oligodeoxynucleoside (PS-oligo) is more effective in prolonging the aPTT than the phosphorothioate linkage of the oligoribonucleoside 25 analogs, including 2'-O-methylribonucleoside. As expected, oligos 4 and 5 showed the least prolongation of aPTT, due to the dominant content of the 2'-O-methylribonucleoside and the least content of phosphorothioate linkages (Table 1). The concentration required for oligos 4 and 5 to prolong 50% aPTT was more than 200 µg/ml (>35 µM). In general, the prolongation of aPTT in presence of oligos 1 to 6 was in the order – oligo 1 > oligo 2 > oligo 3 > oligo 6 > oligo 4 > oligo 5. To our satisfaction, oligo 6 – the newly-designated MBO in which flanking sequences contain 2'-O-methylribonucleosides with alternative phosphorothioate and phosphodiester 30 linkages – showed a significant reduction in its ability to prolong aPTT, compared with oligos 1 and 2. The concentration required to prolong aPTT by 50% for oligos 1, 2, and 6 was 37.1, 46.6 and 94.1 µg/ml, respectively (Table 1).

35

#### Example 6

##### In vivo stability of a POPS block-containing oligonucleotide

40

Prompted by the above *in vitro* results, we extended our study to compare the *in vivo* stability of oligo 6 with that of oligo 1. Oligo 1 and 6 (1 mg) were administered intravenously in mice (female, CD-1, 20-22g) through the tail vein. Following intravenous administration on these two oligos in mice, blood samples were drawn 45 from mice at the post-dosing time points of 30min., 1, 12 and 24 hours. The oligo components were then carefully extracted from the plasma. Part of the oligo samples was analyzed by 20% polyacrylamide gel electrophoresis (PAGE) after the 5'-end labeling with <sup>32</sup>P, and part of the oligo samples was subjected to direct CGE analysis

(with a UV detector). The PAGE autoradiograph showed presence of bands representing intact length of oligo 6 at much longer time points compared with oligo 1 (data not shown). The increased *in vivo* stability of oligo 6, compared with oligo 1, was also confirmed by the CGE analysis. The CGE profile of oligo 1 showed approximately 55% intact oligo and 45% in degraded form, where as majority of oligo 6 was in intact form (Figure 5). In conclusion, our studies demonstrate that it is possible to optimize the properties of antisense oligos by subtle structural changes in the nucleoside sugar residue and internucleotide, as exemplified by the design of oligo 6. Our preliminary pharmacokinetic study also showed that the tissue disposition profile of oligo 6 is similar to that of oligo 2, which suggests that reduction of the phosphorothioate linkages in oligo 6 does not result in significant changes in tissue deposition (data not shown). Other studies are ongoing to fully exploit the therapeutic potential of oligo 6. Similar design of antisense oligos is applying to other disease models.

15

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## Recommended literature

1. Agrawal, S. *Trends Biotechnol.*, 1996, 14, 376.
- 5 2. Altmann, K; Dean, N.; Fabbro, D.; Freier, S.; Geiger, T.; Haner, R.; Husken, D.; Martin, P.; Monia, B.; Muller, M.; Natt, F.; Nicklin, P.; Phillips, J.; Pieleles, U.; Sasmor, H.; Moser, H. *Chimia*, 1996, 50, 168.
3. (a) Agrawal, S.; Mayrand, S.; Zamecnik, P.; Pederson, T. *Proc. Natl. Acad Sci. USA*, 1990, 87, 1401. (b) Devlin, T.; Iyer, R.; Johnson, S.; Agrawal, S. *Bioorg. Med. Chem. Lett.*, 1996, 6, 2663. (c) Giles, R.; Spiller, D.; Tidd, D., *Antisense Res. Dev.*, 1995, 5, 23. (d) Iyer, R.; Yu, D.; Jiang, Z.; Agrawal, S. *Tetrahedron*, 1996, 52, 14419.
- 10 4. (a) Metelev, V.; Lisziewicz, J.; Agrawal, S. *Bioorg. Med. Chem. Lett.*, 1994, 4, 2929. (b) Metelev, V.; Agrawal, S. *Proceeding of International Conferences on Nucleic Acid Medical Applications*, Cancun, Jan. 1993, Abstract 1-1. (c) Monia B.; Lesnik, E.; Gonzalez, C.; Lima, W.; McGee, D.; Guinosso, C.; Kawasaki, A.; Cook, P. J. *Biol. Chem.*, 1993, 268, 14514. (d) Yu, D.; Iyer, R.; Shaw, D.; Lisziewicz, J.; Li, Y.; Jiang, Z.; Roskey, A.; Agrawal, S. *Bioorg. Med. Chem.*, 1996, 4, 1685.
- 15 5. Zhao, Q.; Temsamani, J.; Iadarola, P.; Jiang, Z.; Agrawal, S. *Biocheml Pharmacol.*, 1996, 51, 173.
- 20 6. Shaw, D.; Rustagi, P.; Kandimalla, E.; Manning, A.; Jiang, Z.; Agrawal, S. *Bioch. Pharmacol.*, 1997, 53, 1123.
7. Agrawal, S.; Jiang, Z. Zhao, Q.; Shaw, D.; Cai, Q.; Roskey, A.; Channavajjala, L.; Saxinger, C.; Zhang, R. *Proc. Natl. Acad Sci. USA*, 1997, 94, 2620.
- 25 8. Zhang, R.; Lu, Z.; Liu, T.; Zhao, H.; Zhang, X.; Diasio, S.; Habus, I.; Jiang, Z.; Iyer, R.; Yu, D.; Agrawal, S. *Biochem. Pharmacol.*, 1995, 50, 545.
9. Agrawal, S.; Zhang, X.; Zhao, H.; Lu, Z.; Yan, J.; Cai, H.; Diasio, R.; Habus, I.; Jiang, Z.; Iyer, R.; Yu, D.; Zhang, R. *Biochem. Pharmacol.*, 1995, 50, 571.
10. Nesterova, M.; Cho-Chung, Y. *Nat. Med.* 1995, 1, 528.
11. Agrawal, S.; Zhao, Q. *Antisense Res. Dev.*, in press.
- 30 12. Grindel, J.; Musick, T.; Jiang, Z.; Roskey, Al; Agrawal, S. *Antisense Res. Dev.*, 1998, 8, 43.